MTP-IIGC LTD
About
MTP-IIGC LTD, known as MTPConnect, is Australia's Life Sciences Innovation Accelerator. It supports Australia's medical products sector by fostering connections between research and industry, driving the translation and commercialisation of scientific and technological breakthroughs for better health outcomes.
Tips for Applicants
Applicants should demonstrate strong commercialisation potential, highlight collaborative efforts between research and industry, and clearly articulate how their innovative medical products or solutions will address unmet health needs within the Australian life sciences sector. Emphasise the translational aspect of the research and its pathway to market.
Giving Philosophy
MTPConnect aims to maximise opportunities for Australians to make scientific and technological breakthroughs that are successfully translated and commercialised. They achieve this by improving collaboration, providing and facilitating funding, developing skills, informing policy, and promoting regulatory reform, with a focus on supporting life sciences innovations through commercialisation support programs.
Notable Grants
Giving History
ACNC Financial History
| Year | Grants Given | Revenue | Total Assets | Net Assets |
|---|---|---|---|---|
| FY2023 | $33.5M | $43.3M | $66.8M | $1.4M |
| FY2022 | $32.8M | $40.3M | $90.2M | $1.4M |
| FY2021 | $26.4M | $33.6M | $72.5M | $1.1M |
| FY2020 | $9.1M | $15.1M | $44.9M | $235K |
| FY2019 | $9.7M | $13.7M | $31.9M | $102K |
| FY2018 | $3.7M | $7.0M | $21.3M | $61K |
| 6yr total | $115.2M | Source: ACNC Annual Information Statements | ||
Programs (from website)
TTRA Devices Round 2 investment opportunity
Funding call for eligible Australian start-ups, spin-outs and SMEs to develop innovative preventative, diagnostic, therapeutic and/or disease management devices for cardiovascular disease and the complications of diabetes (type 1 and type 2).